{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-22-000115","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2022-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.710603+00:00","generated_at":"2026-06-21T06:22:16.250991+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Centessa reports 93% bleed reduction with SerpinPC in 18-month OLE; no safety signals","bullets":["Median all-bleeds ABR reduced 93% at 1.2 mg/kg every 2 weeks; median ABR 2.2, 7 of 21 subjects zero bleeds.","No thromboembolic events or treatment-related D-dimer elevations over 18 months; no SerpinPC-related AEs.","Pivotal program advancing: PRESent-5 observation study to start in coming weeks; interventional studies planned for 2023.","Total exposure over 40 patient-years across multiple dosing regimens; sustained safety and tolerability."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-22-000115","json":"https://secwatch.observer/filing/0001847903-22-000115.json","markdown":"https://secwatch.observer/filing/0001847903-22-000115.md","text":"https://secwatch.observer/filing/0001847903-22-000115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790322000115/0001847903-22-000115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790322000115/cnta-20221210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:22:16.250991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}